Brittany Lovely

Quizartinib, a novel small molecule FLT3 inhibitor, is moving through the pipeline of new drugs under development for patients with FLT3-mutated acute myeloid leukemia, part of a menu of targeted treatment options that is expanding as investigators learn more about the molecular heterogeneity of the disease.

Investigators at Cleveland Clinic have demonstrated that the direct oral anticoagulant rivaroxaban significantly reduces venous thromboembolism (VTE) and VTE-related death for patients with high-risk cancers treated in the outpatient setting.

Napabucasin, a novel therapy that targets cancer stem cell pathways, is being investigated in a phase III clinical trial that is believed to be the largest study ever conducted in pancreatic ductal adenocarcinoma in the metastatic setting

Breast surveillance is essential when determining whether or not therapy is beneficial and to avoid toxicity, usual care for patients with metastatic breast cancer includes monitoring of symptoms and cancer burden.

Keith T. Flaherty, MD, discussed the distinguishing features of the combination of encorafenib with binimetinib as well as some next steps, including the question of whether the regimen eventually could move to the adjuvant setting.

A recently launched clinical trial aims to improve outcomes and quality of life for patients with nasal and paranasal squamous cell carcinoma (NPNSCC), a rare type of head and neck cancer that is challenging to treat and carries significant morbidity.

Although multiple checkpoint inhibitors have been introduced into the bladder cancer treatment paradigm during the past several years, their use in the malignancy remains an unfolding story.

Ian W. Flinn, MD, PhD, discusses the potential impact of duvelisib on patients with chronic lymphocytic leukemia.

In en effort to ensure that study participants are more reflective of real-world populations, the National Cancer Institute has revised its clinical trial protocols to expand access for previously excluded patients.

Investigators are taking a personalized approach to treating patients with multiple myeloma by introducing novel agents in combination with backbone chemotherapies, based on patients’ individual genetic profiles.

Endocrine therapy, commonly used for lengthy periods in the adjuvant treatment of patients with breast cancer, does not have a detrimental effect on cognitive function in survivors of early-stage disease.

Some immune-related adverse events associated with immune checkpoint inhibitor therapies may prove to be higher than the data reported in the trials that led to the drugs’ initial FDA approval.